Literature DB >> 25644251

Definitive intensity-modulated radiotherapy compared with definitive conventional radiotherapy in cervical oesophageal squamous cell carcinoma.

Caineng Cao1, Jingwei Luo, Li Gao, Guozhen Xu, Junlin Yi, Xiaodong Huang, Kai Wang, Shiping Zhang, Yuan Qu, Suyan Li, Jianping Xiao, Zhong Zhang.   

Abstract

PURPOSE: The authors compared definitive intensity-modulated radiotherapy (IMRT) with definitive conventional radiotherapy (2D-RT) in cervical oesophageal squamous cell carcinoma (CESCC).
MATERIALS AND METHODS: A total of 101 patients with CESCC treated with definitive radiotherapy from January 2001 to April 2012 were analysed. 37 patients were irradiated using 2D-RT, whereas 64 cases were treated using IMRT.
RESULTS: The median follow-up time was 15.5 months for all the patients. For all patients, the overall 2-year local failure-free survival (LFFS), regional failure-free survival (RFFS), and overall survival (OS) rate was 67.4, 85.2 and 46.2%, respectively. The 2-year LFFS rate and the 2-year RFFS rate in the IMRT group were higher than the 2D-RT group, although no statistically significant difference was observed in LFFS and RFFS. No statistically significant difference was observed in overall survival (OS) between the groups. Compared with 2D-RT, the rate of grade 3 dysphagia after radiotherapy was lower (6.3 vs. 8.1%) and none had hypothyroidism requiring lifelong thyroxine replacement in the IMRT group. Matched-cases analysis did not show a statistical difference in terms of LFFS, RFFS and OS between the groups.
CONCLUSIONS: Although no statistically significant difference was observed in OS, LFFS and RFFS between the IMRT group and the 2D-RT group, the incidence of late toxicity declined using IMRT, thereby resulting in an improved therapeutic ratio for patients with CESCC.

Entities:  

Mesh:

Year:  2015        PMID: 25644251     DOI: 10.1007/s11547-015-0510-8

Source DB:  PubMed          Journal:  Radiol Med        ISSN: 0033-8362            Impact factor:   3.469


  24 in total

1.  Cervical esophageal cancer: a population-based study.

Authors:  G Daniel Grass; S Lewis Cooper; Kent Armeson; Elizabeth Garrett-Mayer; Anand Sharma
Journal:  Head Neck       Date:  2014-06-19       Impact factor: 3.147

2.  Swallowing function after chemoradiation for advanced stage oropharyngeal cancer.

Authors:  Samuel G Shiley; Christopher A Hargunani; Judith M Skoner; John M Holland; Mark K Wax
Journal:  Otolaryngol Head Neck Surg       Date:  2006-03       Impact factor: 3.497

Review 3.  Radiation dose-volume effects in the larynx and pharynx.

Authors:  Tiziana Rancati; Marco Schwarz; Aaron M Allen; Felix Feng; Aron Popovtzer; Bharat Mittal; Avraham Eisbruch
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-03-01       Impact factor: 7.038

4.  Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01). Radiation Therapy Oncology Group.

Authors:  J S Cooper; M D Guo; A Herskovic; J S Macdonald; J A Martenson; M Al-Sarraf; R Byhardt; A H Russell; J J Beitler; S Spencer; S O Asbell; M V Graham; L L Leichman
Journal:  JAMA       Date:  1999-05-05       Impact factor: 56.272

5.  Intensity-modulated radiation therapy with concurrent chemotherapy for locally advanced cervical and upper thoracic esophageal cancer.

Authors:  Shu-Lian Wang; Zhongxing Liao; Helen Liu; Jaffer Ajani; Stephen Swisher; James D Cox; Ritsuko Komaki
Journal:  World J Gastroenterol       Date:  2006-09-14       Impact factor: 5.742

6.  Dose-response relationship in locoregional control for patients with stage II-III esophageal cancer treated with concurrent chemotherapy and radiotherapy.

Authors:  Zhen Zhang; Zhongxing Liao; Jing Jin; Jaffer Ajani; Joe Y Chang; Melenda Jeter; Thomas Guerrero; Craig W Stevens; Stephen Swisher; Linus Ho; James Yao; Pamela Allen; James D Cox; Ritsuko Komaki
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-03-01       Impact factor: 7.038

7.  Dosimetric comparison of IMRT vs. 3D conformal radiotherapy in the treatment of cancer of the cervical esophagus.

Authors:  Louis Fenkell; Inna Kaminsky; Stephen Breen; Sophie Huang; Monique Van Prooijen; Jolie Ringash
Journal:  Radiother Oncol       Date:  2008-09-12       Impact factor: 6.280

8.  Treatment of base of tongue cancer with paclitaxel, ifosfamide, and cisplatinum induction chemotherapy followed by chemoradiotherapy.

Authors:  Samuel Brandon Hancock; Greg A Krempl; Vikki Canfield; Carl Bogardus; Kiarash Kojouri; S K Kaneaster; Jesus E Medina
Journal:  Laryngoscope       Date:  2008-08       Impact factor: 3.325

9.  Management of Cervical Esophageal Carcinoma.

Authors: 
Journal:  Semin Radiat Oncol       Date:  1994-07       Impact factor: 5.934

10.  Swallowing disorders in the first year after radiation and chemoradiation.

Authors:  Jeri A Logemann; Barbara Roa Pauloski; Alfred W Rademaker; Cathy L Lazarus; Joy Gaziano; Linda Stachowiak; Lisa Newman; Ellen MacCracken; Daphne Santa; Bharat Mittal
Journal:  Head Neck       Date:  2008-02       Impact factor: 3.147

View more
  5 in total

1.  Outcome of proximal esophageal cancer after definitive combined chemo-radiation: a Swiss multicenter retrospective study.

Authors:  Evelyn Herrmann; Nando Mertineit; Berardino De Bari; Laura Hoeng; Francesca Caparotti; Dominic Leiser; Raphael Jumeau; Nikola Cihoric; Alexandra D Jensen; Daniel M Aebersold; Mahmut Ozsahin
Journal:  Radiat Oncol       Date:  2017-06-14       Impact factor: 3.481

2.  What is the optimal radiation dose for non-operable esophageal cancer? Dissecting the evidence in a meta-analysis.

Authors:  Yong Chen; Hui-Ping Zhu; Tao Wang; Chang-Jiang Sun; Xiao-Lin Ge; Ling-Feng Min; Xian-Wen Zhang; Qing-Qing Jia; Jie Yu; Jian-Qi Yang; Heike Allgayer; Mohammed L Abba; Xi-Zhi Zhang; Xin-Chen Sun
Journal:  Oncotarget       Date:  2017-06-28

3.  Intensity-Modulated Radiotherapy versus Three-Dimensional Conformal Radiotherapy in Definitive Chemoradiotherapy for Cervical Esophageal Squamous Cell Carcinoma: Comparison of Survival Outcomes and Toxicities.

Authors:  Nai-Bin Chen; Bo Qiu; Jun Zhang; Meng-Yun Qiang; Yu-Jia Zhu; Bin Wang; Jin-Yu Guo; Ling-Zhi Cai; Shao-Min Huang; Meng-Zhong Liu; Qun Li; Yong-Hong Hu; Qi-Wen Li; Hui Liu
Journal:  Cancer Res Treat       Date:  2019-04-30       Impact factor: 4.679

4.  The Application of Nimotuzumab Combined With Definitive Chemoradiotherapy Toward the Treatment of Locally Advanced Cervical Esophageal Carcinoma: A Retrospective Study.

Authors:  Jing Hu; Zhe Chen; Jiaming Lv; Zhen Zheng; Yanping Bei; Xue Chen; Lu Zheng; Wenjie Song; Yunbao Xu
Journal:  Front Oncol       Date:  2022-07-06       Impact factor: 5.738

5.  Radiation dose escalation by simultaneous modulated accelerated radiotherapy combined with chemotherapy for esophageal cancer: a phase II study.

Authors:  Jianzhou Chen; Hong Guo; Tiantian Zhai; Daniel Chang; Zhijian Chen; Ruihong Huang; Wuzhe Zhang; Kun Lin; Longjia Guo; Mingzhen Zhou; Dongsheng Li; Derui Li; Chuangzhen Chen
Journal:  Oncotarget       Date:  2016-04-19
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.